Marisa Wexler, MS, senior science writer —

A dysregulated immune response against viruses that cause hepatitis may lead to some cases of multiple myeloma (MM) — and in these cases, treating the viral infection may improve the patient’s odds of survival. That’s according to a new study titled “Impact of viral hepatitis therapy…

Adding Darzalex Faspro (daratumumab and hyaluronidase) — a subcutaneous or under-the-skin formulation of Darzalex (daratumumab) — to a standard combination therapy regimen led to significantly better outcomes for people who are newly diagnosed with multiple myeloma and transplant eligible. That’s according to four-year data from the Phase 3…

The U.S. Food and Drug Administration (FDA) is delaying its review of an application that seeks to allow the cell therapy Abecma (idecabtagene vicleucel) to be used earlier in the treatment of difficult-to-manage multiple myeloma. Abecma currently is FDA-approved for adults with relapsed or refractory multiple myeloma (RRMM) who…

A committee of the European Medicines Agency (EMA) has recommended that Elrexfio (elranatamab) — a therapy already in use in the U.S. — be conditionally approved for treating people in Europe with relapsed or refractory multiple myeloma (RRMM). The recommendation, from the EMA’s Committee for Medicinal Products…

While diabetes is more frequent among Black people than white people, it’s associated with poorer survival outcomes in white people with multiple myeloma, a U.S. study shows. “We knew from prior studies that patients with multiple myeloma and diabetes have lower survival rates. But what we did not know…

People with hard-to-treat multiple myeloma given a regimen of Venclexta (venetoclax) plus dexamethasone lived longer than those treated with Pomalyst (pomalidomide) plus the corticosteroid, according to data from a Phase 3 clinical trial. Results from the trial, dubbed CANOVA (NCT03539744), also showed that the Venclexta combo was…

Nanjing Leads Biolabs is planning to launch a first-in-human clinical trial to test LBL-034, an antibody-based therapy designed to trigger the immune system to destroy cancer cells, in people with relapsed or refractory multiple myeloma in the U.S. and China. Leads Biolabs has received approval to launch the…

Researchers at Tel Aviv University in Israel have developed a new nanoparticle system that can deliver RNA-based therapies designed to kill myeloma cells in bone marrow. Nanoparticle-mediated delivery of an RNA therapy specifically designed to reduce levels of CKAP5 — a protein required for cancer cells to grow and…

The U.S. Food and Drug Administration (FDA) has placed a hold on clinical testing of CART-ddBCMA, a cell therapy that Arcellx and Kite Pharma are co-developing for people with relapsed and refractory multiple myeloma (rrMM), following the death of a patient enrolled in the trial. The move pauses the…

Carvykti (ciltacabtagene autoleucel) significantly reduces the risk of disease progression or death in adults with multiple myeloma who received one to three prior lines of therapy and failed to respond to standard Revlimid (lenalidomide). That’s according to the first data analysis, at nearly 1.5 years of follow-up,…